CRISPR in research and treatment of multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R8B" target="_blank" >RIV/61988987:17110/17:A1801R8B - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/17:E0106565
Result on the web
<a href="http://dx.doi.org/10.14735/amko20172S68" target="_blank" >http://dx.doi.org/10.14735/amko20172S68</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amko20172S68" target="_blank" >10.14735/amko20172S68</a>
Alternative languages
Result language
angličtina
Original language name
CRISPR in research and treatment of multiple myeloma
Original language description
In the recent years, there was a remarkable advance in research and clinical implementation of the genome editing technologies. The most remarkable was a discovery of the bacterial adaptive immune system called CRISPR and its rapid transformation into a robust and broadly applicable technology that completely revolutionized both basic and applied bio medical research. Implementation of CRISPR makes genome modification easier, faster and significantly cheaper compare to any other currently available technology. It also offers a tremendous potential for designing novel research approaches and future treatment options for various genetic diseases including multiple myeloma. The high trough put use of CRISPR in pooled screen formats promises faster identification and validation of valuable drug targets together with revealing high-confidence bio markers and unknown resistance mechanisms. This can provide clinicians with new diagnostic and prognostic tolls and ultimately allow more accurate patient stratification for personalised treatment with better efficacy. In this review, we summarize current knowledge about the CRISPR technology and focus especially on its impact in exploring gene functions, screening for novel drug targets, diagnostic markers and genes involved in resistance to commonly used drug in the treatment of multiple myeloma. Finally, we also highlight a potential future use of CRISPR in actual clinical practise.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Klinicka Onkologie
ISSN
0862-495X
e-ISSN
—
Volume of the periodical
30
Issue of the periodical within the volume
6/2017
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
7
Pages from-to
68-74
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85029475392